Satellos Bioscience Inc.
MSCL.TO
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 65.16% | -32.82% | |||
| Gross Profit | -65.16% | 32.82% | |||
| SG&A Expenses | 23.59% | -0.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 50.39% | -23.96% | |||
| Operating Income | -50.39% | 23.96% | |||
| Income Before Tax | 34.25% | -50.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 34.25% | -50.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.25% | -50.39% | |||
| EBIT | -50.39% | 23.96% | |||
| EBITDA | -50.24% | 23.97% | |||
| EPS Basic | 38.33% | -50.13% | |||
| Normalized Basic EPS | -9.71% | 15.57% | |||
| EPS Diluted | 38.33% | -50.13% | |||
| Normalized Diluted EPS | -9.71% | 15.57% | |||
| Average Basic Shares Outstanding | 6.61% | 0.20% | |||
| Average Diluted Shares Outstanding | 6.61% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
